The epidermal growth factor receptor as a target for colorectal cancer therapy

Schlessinger, 2000, Cell signaling by receptor tyrosine kinases, Cell, 103, 211, 10.1016/S0092-8674(00)00114-8 Yarden, 2001, Untangling the ErbB signalling network, Nature Rev Mol Cell Biol, 2, 127, 10.1038/35052073 Arteaga, 2002, Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia, Semin Oncol, 29, 3, 10.1053/sonc.2002.35642 Mendelsohn, 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J Clin Oncol, 21, 2787, 10.1200/JCO.2003.01.504 Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I Di Marco, 1989, Autocrine interaction between TGF alpha and the EGF-receptor, Oncogene, 4, 831 Tong, 1998, Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells, Br J Cancer, 77, 1792, 10.1038/bjc.1998.298 Yasui, 1988, Expression of epidermal growth factor receptor in human gastric and colonic carcinomas, Cancer Res, 48, 137 Ciardiello, 1991, Differential expression of epidermal growth factor-related proteins in human colorectal tumors, Proc Natl Acad Sci U S A, 88, 7792, 10.1073/pnas.88.17.7792 Hayashi, 1994, Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues, Pathol Int, 44, 124, 10.1111/j.1440-1827.1994.tb01696.x Messa, 1998, EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma, Acta Oncol, 37, 285, 10.1080/028418698429595 Malecka-Panas, 1996, Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats, Carcinogenesis, 17, 233, 10.1093/carcin/17.2.233 Coffey, 1992, Transforming growth factors and related peptides in gastrointestinal neoplasia, J Cell Biochem, 16G, 111, 10.1002/jcb.240501120 Roberts, 2002, Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis, Proc Natl Acad Sci U S A, 99, 1521, 10.1073/pnas.032678499 Threadgill, 1995, Targeted disruption of mouse EGF receptor, Science, 269, 230, 10.1126/science.7618084 Moscatello, 1998, Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor, J Biol Chem, 273, 200, 10.1074/jbc.273.1.200 Rodrigues, 2003, Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells, Oncogene, 22, 4488, 10.1038/sj.onc.1206685 Chen, 1993, Epidermal growth factor (EGF) promotes human keratinocyte locomotion on collagen by increasing the alpha 2 integrin subunit, Exp Cell Res, 209, 216, 10.1006/excr.1993.1304 Lund-Johansen, 1990, Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro, Cancer Res, 50, 6039 Brunton, 1997, A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer, Oncogene, 14, 283, 10.1038/sj.onc.1200827 Ciardiello, 1993, Infection with a transforming growth factor alpha anti-sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line, Int J Cancer, 54, 952, 10.1002/ijc.2910540615 Karnes, 1992, Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody, Gastroenterology, 102, 474, 10.1016/0016-5085(92)90093-E Karameris, 1993, Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases, Pathol Res Pract, 189, 133, 10.1016/S0344-0338(11)80082-8 Rajagopal, 1995, Epidermal growth factor expression in human colon and colon carcinomas, Int J Cancer, 62, 661, 10.1002/ijc.2910620603 Karnes, 1998, Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells, Gastroenterology, 114, 930, 10.1016/S0016-5085(98)70312-9 Rosen, 2001, Transforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, and apoptosis of intestinal epithelial cells, J Biol Chem, 276, 37273, 10.1074/jbc.M106424200 Detmar, 1994, Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis, J Exp Med, 180, 1141, 10.1084/jem.180.3.1141 Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am J Pathol, 151, 1523 Perrotte, 1999, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice, Clin Cancer Res, 5, 257 Ciardiello, 2001, Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor, Clin Cancer Res, 7, 1459 Ravindranath, 2001, Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate, J Androl, 22, 432 O’Dwyer, 2002, Epidermal growth factor receptor-targeted therapy in colorectal cancer, Semin Oncol, 29, 10, 10.1053/sonc.2002.35643 Kluftinger, 1992, Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer, Surg Oncol, 1, 97, 10.1016/0960-7404(92)90062-P Steele, 1990, Epidermal growth factor receptor expression in colorectal cancer, Br J Surg, 77, 1352, 10.1002/bjs.1800771211 Koretz, 1990, Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma, Virchows Arch A, 416, 343, 10.1007/BF01605295 Mayer, 1993, The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer, Cancer, 71, 2454, 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2 De Jong, 1998, Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors, Hepatology, 28, 971, 10.1002/hep.510280411 Radinsky, 1995, Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells, Clin Cancer Res, 1, 19 McKay, 2002, Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases, Eur J Cancer, 38, 2258, 10.1016/S0959-8049(02)00234-4 Ozawa, 1989, Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor, Int J Cancer, 43, 152, 10.1002/ijc.2910430128 Chaudhary, 1987, Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin, Proc Natl Acad Sci U S A, 84, 4538, 10.1073/pnas.84.13.4538 Yamazaki, 1998, Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression, J Natl Cancer Inst, 90, 581, 10.1093/jnci/90.8.581 Ciardiello, 2001, Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines, Int J Cancer, 93, 172, 10.1002/ijc.1335 Jannot, 1996, Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells, Oncogene, 13, 275 Mendelsohn, 1997, Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy, Clin Cancer Res, 3, 2703 Divgi, 1991, Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma, J Natl Cancer Inst, 83, 97, 10.1093/jnci/83.2.97 Goldstein, 1995, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model, Clin Cancer Res, 1, 1311 Yang, 2001, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Crit Rev Oncol Hematol, 38, 17, 10.1016/S1040-8428(00)00134-7 Baselga, 2001, The EGFR as a target for anticancer therapy-focus on cetuximab, Eur J Cancer, 37, S16, 10.1016/S0959-8049(01)00233-7 Arteaga, 1997, Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site, J Biol Chem, 272, 23247, 10.1074/jbc.272.37.23247 Lichtner, 2001, Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors, Cancer Res, 61, 5790 Mellinghoff, 2002, Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts, Cancer Res, 62, 5254 Wu, 1995, Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin, J Clin Invest, 95, 1897, 10.1172/JCI117871 Saltz, 2001, Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR), Proc Am Soc Clin Oncol, 20, 7 Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 Rosenberg, 2002, Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr), Proc Am Soc Clin Oncol, 21, 135a Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Figlin, 2002, ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer, Proc Am Soc Clin Oncol, 21, 35 Meropol, 2003, Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol, 22, 256 Ciardiello, 2000, Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor, Clin Cancer Res, 6, 2053 Braun, 2002, Preclinical evaluation of the combination of epidermal growth factor inhibitor ZD1839 (Iressa) and irinotecan (SN-38) in human colon cancer cells, Proc Am Soc Clin Oncol, 21, 329 Baselga, 2002, Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types, J Clin Oncol, 20, 4292, 10.1200/JCO.2002.03.100 Herbst, 2002, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors, J Clin Oncol, 20, 3815, 10.1200/JCO.2002.03.038 Nakagawa, 2003, Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors, Ann Oncol, 14, 922, 10.1093/annonc/mdg250 Ranson, 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors, J Clin Oncol, 20, 2240, 10.1200/JCO.2002.10.112 Hammond, 2001, Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer, Proc Am Soc Clin Oncol, 20, 544 Cho, 2002, A phase I study of ZD1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies, Proc Am Soc Clin Oncol, 21, 38 Basche, 2003, A phase I trial of ZD1839 (Z) with capecitabine (Cp) and celecoxib (Cel) in patients (pts) with advanced solid tumors, Proc Am Soc Clin Oncol, 22, 209 Goss, 2002, Initial results of part 2 of a phase I/II pharmacokinetics (PK), pharmacodynamic (PD) and biological activity study of ZD1839 (Iressa), Proc Am Soc Clin Oncol, 21, 59 Rothenberg, 2004, Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839), Proc Am Soc Clin Oncol, 22, 3000, 10.1200/jco.2004.22.14_suppl.3000 Moyer, 1997, Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase, Cancer Res, 57, 4838 Hidalgo, 2001, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J Clin Oncol, 19, 3267, 10.1200/JCO.2001.19.13.3267 Karp, 1999, Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774 in patients with advanced solid tumors, Proc Am Soc Clin Oncol, 19, 1499 Rowinsky, 2001, Dose-schedule-finding, pharmacokinetic (PK), biologic, and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, Proc Am Soc Clin Oncol, 21, 5 Oza, 2003, Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol, 22, 196 DeSimone, 2002, A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers, Proc Am Soc Clin Oncol, 21, 375 Adams, 2002, A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects, Proc Am Soc Clin Oncol, 21, 374 Burris, 2003, A phase I study of GW572016 in patients with solid tumors, Proc Am Soc Clin Oncol, 22, 248 Belanger, 2003, A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU5-FU in combination with irinotecan and/or oxaliplatin, Proc Am Soc Clin Oncol, 22, 244 De Bono, 2003, Phase I and pharmacokinetic (PK) study of oral GW572016, a potent reversible dual inhibitor of both erbB1 and erbB2 tyrosine kinase (TK), administered in combination with capecitabine, Proc Am Soc Clin Oncol, 22, 225 Bonomi, 2003, Clinical studies with non-iressa EGFR tyrosine kinase inhibitors, Lung Cancer, 41, 43, 10.1016/S0169-5002(03)00141-7 Dumez, 2002, A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer, Proc Am Soc Clin Oncol, 21, 341 Hoekstra, 2002, A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer, Proc Am Soc Clin Oncol, 21, 340 Murren, 2002, A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers, Proc Am Soc Clin Oncol, 21, 377 Erlichman, 2001, The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux, Cancer Res, 61, 739 Garrison, 2001, A phase 1 and pharmacokinetic study of CI-1033, a Pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors, Proc Am Soc Clin Oncol, 20, 283 Shin, 2001, A phase I clinical and biomarker study of CI-1033, a novel Pan-ErbB tyrosine kinase inhibitor in patients with solid tumors, Proc Am Soc Clin Oncol, 21, 324 Rinehart, 2002, A phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors, Proc Am Soc Clin Oncol, 21, 41 Nemunaitis, 2003, A phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors, Proc Am Soc Clin Oncol, 22, 243 Rinehart, 2003, A phase I clinical and pharmacokinetic (PK)/food effect study of oral CI-1033, a pan-erb B tyrosine kinase inhibitor, in patients with advanced solid tumors, Proc Am Soc Clin Oncol, 22, 205 Hidalgo, 2002, Phase 1 trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors, Proc Am Soc Clin Oncol, 21, 65 Salazar, 2003, A phase 1/2A open-label study of EKB-569 in combination with CPT-11/5-FU/LV (FOLFIRI) in patients with advanced colorectal cancer, Proc Am Soc Clin Oncol, 22, 222 Folprecht, 2003, Pharmacokinetic (PK) evaluation of cetuximab in combination with weekly irinotecan (CPT-11) and 24h infusional 5-FU/folinic acid (FA) as first line treatment in patients (pts) with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (MCRC), Proc Am Soc Clin Oncol, 22, 890 Polowy, 2003, Predictive value of epidermal growth factor receptor(EGFR) levels by fluorescence-in-situ-hybridization (FISH) and immunohistochemistry (IHC) in non-small cell lung cancer (NSCLC) patients treated with ZD1839 (Iressa), Proc Am Soc Clin Oncol, 22, 2845 Stoehlmacher, 2001, Association between mRNA expression level of epidermal growth factor receptor (EGFR), immunohistochemistry (IHC) and response to the EGFR-inhibitor C225 in advanced colorectal carcinoma, Proc Am Soc Clin Oncol, 20, 593 Cohen, 2003, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck, J Clin Oncol, 21, 1980, 10.1200/JCO.2003.10.051 Perez-Soler, 2003, Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?, Oncology (Huntingt), 17, 23 Soulieres, 2004, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck, J Clin Oncol, 22, 77, 10.1200/JCO.2004.06.075 Perez-Soler, 2001, A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 20, 1235 Finkler, 2001, Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma, Proc Am Soc Clin Oncol, 20, 831 Saltz, 2003, The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies, Proc Am Soc Clin Oncol, 22, 817 Rothenberg, 2003, Improving the evaluation of new cancer treatments, Cancer, 3, 303 Rowinsky, 2000, The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents, Drugs, 60, 1, 10.2165/00003495-200060001-00001 Schilsky, 2002, End points in cancer clinical trials and the drug approval process, Clin Cancer Res, 8, 935 Stadler, 2000, Development of target-based antineoplastic agents, Invest New Drugs, 18, 7, 10.1023/A:1006371512390